Th17 cells in inflammation and autoimmunity

Autoimmunity Reviews

Volumn 13, Issue 12, 2014, Pages 1174-1181

  Singh, Ram Pyare ^a   Hasan, Sascha ^a   Sharma, Sherven ^a   Nagra, Saranpreet ^a   Yamaguchi, Dean T ^a   Wong, David T W ^a   Hahn, Bevra H ^a   Hossain, Awlad ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoimmunity; Cancer; Mesenchymal stem cells; Sex hormones; Systemic lupus erythematosus; Th17

Indexed keywords

SEX HORMONE; INTERLEUKIN 17;

ASTHMA; AUTOIMMUNITY; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; MALIGNANT NEOPLASTIC DISEASE; MESENCHYMAL STEM CELL; NONHUMAN; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; ANIMAL; AUTOIMMUNE DISEASE; IMMUNOLOGY; MESENCHYMAL STROMA CELL;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; GONADAL STEROID HORMONES; HUMANS; INFLAMMATION; INTERLEUKIN-17; MESENCHYMAL STROMAL CELLS; TH17 CELLS;

EID: 84908870251     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2014.08.019     Document Type: Review

References (117)

1. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005, 6:1123-1132.
2. Brusko T.M., Koya R.C., Zhu S., Lee M.R., Putnam A.L., McClymont S.A., et al. Human antigen-specific regulatory T cells generated by T cell receptor gene transfer. PLoS One 2010, 5:e11726.
3. Duhen T., Geiger R., Jarrossay D., Lanzavecchia A., Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009, 10:857-863.
4. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
5. Wilson C.B., Rowell E., Sekimata M. Epigenetic control of T-helper-cell differentiation. Nat Rev Immunol 2009, 9:91-105.
6. Hoeve M.A., Savage N.D., de Boer T., Langenberg D.M., de Waal Malefyt R., Ottenhoff T.H., et al. Divergent effects of IL-12 and IL-23 on the production of IL-17 by human T cells. Eur J Immunol 2006, 36:661-670.
7. Korn T., Bettelli E., Gao W., Awasthi A., Jager A., Strom T.B., et al. IL-21 initiates an alternative pathway to induce proinflammatory T(H)17 cells. Nature 2007, 448:484-487.
8. Ivanov I.I., McKenzie B.S., Zhou L., Tadokoro C.E., Lepelley A., Lafaille J.J., Cua D.J., Littman D.R. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006, 126:1121-1133.
9. Yang X.O., Pappu B.P., Nurieva R., Akimzhanov A., Kang H.S., Chung Y., et al. T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma. Immunity 2008, 28:29-39.
10. Ouyang W., Kolls J.K., Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008, 28:454-467.
11. Ghoreschi K., Laurence A., Yang X.P., Hirahara K., O'Shea J.J. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol 2011, 32:395-401.
12. Xu L., Kitani A., Fuss I., Strober W. Cutting edge: regulatory T cells induce CD4+CD25-Foxp3- T cells or are self-induced to become Th17 cells in the absence of exogenous TGF-beta. J Immunol 2007, 178:6725-6729.
13. Chung Y., Chang S.H., Martinez G.J., Yang X.O., Nurieva R., Kang H.S., et al. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 2009, 30:576-587.
14. Osorio F., LeibundGut-Landmann S., Lochner M., Lahl K., Sparwasser T., Eberl G., et al. DC activated via dectin-1 convert Treg into IL-17 producers. Eur J Immunol 2008, 38:3274-3281.
15. Chung D.R., Kasper D.L., Panzo R.J., Chitnis T., Grusby M.J., Sayegh M.H., et al. CD4+ T cells mediate abscess formation in intra-abdominal sepsis by an IL-17-dependent mechanism. J Immunol 2003, 170:1958-1963.
16. Happel K.I., Dubin P.J., Zheng M., Ghilardi N., Lockhart C., Quinton L.J., et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J Exp Med 2005, 202:761-769.
17. Huang W., Na L., Fidel P.L., Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004, 190:624-631.
18. Infante-Duarte C., Horton H.F., Byrne M.C., Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J Immunol 2000, 165:6107-6115.
19. LeibundGut-Landmann S., Gross O., Robinson M.J., Osorio F., Slack E.C., Tsoni S.V., et al. Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17. Nat Immunol 2007, 8:630-638.
20. Ye P., Garvey P.B., Zhang P., Nelson S., Bagby G., Summer W.R., et al. Interleukin-17 and lung host defense against Klebsiella pneumoniae infection. Am J Respir Cell Mol Biol 2001, 25:335-340.
21. Park H., Li Z., Yang X.O., Chang S.H., Nurieva R., Wang Y.H., et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005, 6:1133-1141.
22. Hwang J., Kita R., Kwon H.S., Choi E.H., Lee S.H., Udey M.C., et al. Epidermal ablation of Dlx3 is linked to IL-17-associated skin inflammation. Proc Natl Acad Sci U S A 2011, 108:11566-11571.
23. Kolls J.K., Linden A. Interleukin-17 family members and inflammation. Immunity 2004, 21:467-476.
24. Morrison P.J., Ballantyne S.J., Kullberg M.C. Interleukin-23 and T helper 17-type responses in intestinal inflammation: from cytokines to T-cell plasticity. Immunology 2011, 133:397-408.
25. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006, 314:1461-1463.
26. Yen D., Cheung J., Scheerens H., Poulet F., McClanahan T., McKenzie B., et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J Clin Invest 2006, 116:1310-1316.
27. Yang X., Zheng S.G. Interleukin-22: a likely target for treatment of autoimmune diseases. Autoimmun Rev 2014, 13:615-620.
28. Jiang R., Tan Z., Deng L., Chen Y., Xia Y., Gao Y., et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology 2011, 54:900-909.
29. Yamazaki T., Yang X.O., Chung Y., Fukunaga A., Nurieva R., Pappu B., et al. CCR6 regulates the migration of inflammatory and regulatory T cells. J Immunol 2008, 181:8391-8401.
30. Noubade R., Krementsov D.N., Del Rio R., Thornton T., Nagaleekar V., Saligrama N., et al. Activation of p38 MAPK in CD4 T cells controls IL-17 production and autoimmune encephalomyelitis. Blood 2011, 118:3290-3300.
31. Jirmanova L., Giardino Torchia M.L., Sarma N.D., Mittelstadt P.R., Ashwell J.D. Lack of the T cell-specific alternative p38 activation pathway reduces autoimmunity and inflammation. Blood 2011, 118:3280-3289.
32. Stockinger B., Veldhoen M. Differentiation and function of Th17 T cells. Curr Opin Immunol 2007, 19:281-286.
33. Komiyama Y., Nakae S., Matsuki T., Nambu A., Ishigame H., Kakuta S., et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006, 177:566-573.
34. Doreau A., Belot A., Bastid J., Riche B., Trescol-Biemont M.C., Ranchin B., et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009, 10:778-785.
35. Li H., Nourbakhsh B., Cullimore M., Zhang G.X., Rostami A. IL-9 is important for T-cell activation and differentiation in autoimmune inflammation of the central nervous system. Eur J Immunol 2011, 41:2197-2206.
36. Stromnes I.M., Cerretti L.M., Liggitt D., Harris R.A., Goverman J.M. Differential regulation of central nervous system autoimmunity by T(H)1 and T(H)17 cells. Nat Med 2008, 14:337-342.
37. Tzartos J.S., Friese M.A., Craner M.J., Palace J., Newcombe J., Esiri M.M., et al. Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am J Pathol 2008, 172:146-155.
38. Sato K., Suematsu A., Okamoto K., Yamaguchi A., Morishita Y., Kadono Y., et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006, 203:2673-2682.
39. Geremia A., Biancheri P., Allan P., Corazza G.R., Di Sabatino A. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 2014, 13:3-10.
40. Lin C.H., Kadakia S., Frieri M. New insights into an autoimmune mechanism, pharmacological treatment and relationship between multiple sclerosis and inflammatory bowel disease. Autoimmun Rev 2014, 13:114-116.
41. Cavalcante P., Bernasconi P., Mantegazza R. Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 2012, 25:621-629.
42. Dalakas M.C. Novel future therapeutic options in myasthenia gravis. Autoimmun Rev 2013, 12:936-941.
43. Gertel-Lapter S., Mizrachi K., Berrih-Aknin S., Fuchs S., Souroujon M.C. Impairment of regulatory T cells in myasthenia gravis: studies in an experimental model. Autoimmun Rev 2013, 12:894-903.
44. Osnes L.T., Nakken B., Bodolay E., Szodoray P. Assessment of intracellular cytokines and regulatory cells in patients with autoimmune diseases and primary immunodeficiencies - novel tool for diagnostics and patient follow-up. Autoimmun Rev 2013, 12:967-971.
45. Selmi C., Leung P.S., Sherr D.H., Diaz M., Nyland J.F., Monestier M., et al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J Autoimmun 2012, 39:272-284.
46. Fenoglio D., Bernuzzi F., Battaglia F., Parodi A., Kalli F., Negrini S., et al. Th17 and regulatory T lymphocytes in primary biliary cirrhosis and systemic sclerosis as models of autoimmune fibrotic diseases. Autoimmun Rev 2012, 12:300-304.
47. Niu Q., Cai B., Huang Z.C., Shi Y.Y., Wang L.L. Disturbed Th17/Treg balance in patients with rheumatoid arthritis. Rheumatol Int 2012, 32:2731-2736.
48. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 13:668-677.
49. Lubberts E. IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?. Cytokine 2008, 41:84-91.
50. Kim K.W., Cho M.L., Park M.K., Yoon C.H., Park S.H., Lee S.H., et al. Increased interleukin-17 production via a phosphoinositide 3-kinase/Akt and nuclear factor kappaB-dependent pathway in patients with rheumatoid arthritis. Arthritis Res Ther 2005, 7:R139-R148.
51. Lubberts E., Koenders M.I., Oppers-Walgreen B., van den Bersselaar L., Coenen-de Roo C.J., Joosten L.A., et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum 2004, 50:650-659.
52. Cascao R., Vidal B., Raquel H., Neves-Costa A., Figueiredo N., Gupta V., et al. Effective treatment of rat adjuvant-induced arthritis by celastrol. Autoimmun Rev 2012, 11:856-862.
53. Dong W., Zhu P. Functional niche of inflamed synovium for Th17-cell expansion and activation in rheumatoid arthritis: implication to clinical therapeutics. Autoimmun Rev 2012, 11:844-851.
54. Zhou Z.Y., Chen S.L., Shen N., Lu Y. Cytokines and Behcet's disease. Autoimmun Rev 2012, 11:699-704.
55. Fransen J.H., van der Vlag J., Ruben J., Adema G.J., Berden J.H., Hilbrands L.B. The role of dendritic cells in the pathogenesis of systemic lupus erythematosus. Arthritis Res Ther 2010, 12:207.
56. Shah K., Lee W.W., Lee S.H., Kim S.H., Kang S.W., Craft J., et al. Dysregulated balance of Th17 and Th1 cells in systemic lupus erythematosus. Arthritis Res Ther 2010, 12:R53.
57. Yang J., Chu Y., Yang X., Gao D., Zhu L., Wan L., et al. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1472-1483.
58. Qin W.Z., Chen L.L., Pan H.F., Leng R.X., Zhai Z.M., Wang C., et al. Expressions of IL-22 in circulating CD4+/CD8+ T cells and their correlation with disease activity in SLE patients. Clin Exp Med 2011, 11:245-250.
59. Kang H.K., Liu M., Datta S.K. Low-dose Peptide tolerance therapy of lupus generates plasmacytoid dendritic cells that cause expansion of autoantigen-specific regulatory T cells and contraction of inflammatory th17 cells. J Immunol 2007, 178:7849-7858.
60. Jacob N., Yang H., Pricop L., Liu Y., Gao X., Zheng S.G., et al. Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway. J Immunol 2009, 182:2532-2541.
61. Hsu H.C., Yang P., Wang J., Wu Q., Myers R., Chen J., et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol 2008, 9:166-175.
62. Kwan B.C., Tam L.S., Lai K.B., Lai F.M., Li E.K., Wang G., et al. The gene expression of type 17T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology 2009, 48:1491-1497.
63. Nguyen C.Q., Hu M.H., Li Y., Stewart C., Peck A.B. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjogren's syndrome: findings in humans and mice. Arthritis Rheum 2008, 58:734-743.
64. Sakai A., Sugawara Y., Kuroishi T., Sasano T., Sugawara S. Identification of IL-18 and Th17 cells in salivary glands of patients with Sjogren's syndrome, and amplification of IL-17-mediated secretion of inflammatory cytokines from salivary gland cells by IL-18. J Immunol 2008, 181:2898-2906.
65. Mieliauskaite D., Dumalakiene I., Rugiene R., Mackiewicz Z. Expression of IL-17, IL-23 and their receptors in minor salivary glands of patients with primary Sjogren's syndrome. Clin Dev Immunol 2012, 187258.
66. Miletic M., Stojanovic R., Pajic O., Bugarski D., Mojsilovic S., Cokic V., Milenkovic P. Serum interleukin-17 & nitric oxide levels in patients with primary Sjogren's syn- drome. Indian J Med Res 2012, 135:513-519.
67. Katsifis G.E., Rekka S., Moutsopoulos N.M., Pillemer S., Wahl S.M. Systemic and local interleukin-17 and linked cytokines associated with Sjogren's syndrome immunopathogenesis. Am J Pathol 2009, 175:1167-1177.
68. Nguyen C.Q., Yin H., Lee B.H., Carcamo W.C., Chiorini J.A., Peck A.B. Pathogenic effect of interleukin-17A in induction of Sjogren's syndrome-like disease using adenovirus mediated gene transfer. Arthritis Res Ther 2010, 12:R220.
69. Lavoie T.N., Stewart C.M., Berg K.M., Li Y., Nguyen C.Q. Expression of interleukin-22 in Sjogren's syndrome: significant correlation with disease parameters. Scand J Immunol 2011, 74:377-382.
70. Ciccia F., Guggino G., Rizzo A., Ferrante A., Raimondo S., Giardina A., Dieli F., Campisi G., Alessandro R., Triolo G. Potential involvement of IL-22 and IL-22-producing cells in the inflamed salivary glands of patients with Sjogren's syndrome. Ann Rheum Dis 2012, 71:295-301.
71. Caproni M., Antiga E., Melani L., Volpi W., Del Bianco E., Fabbri P. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009, 29:210-214.
72. Kagami S., Rizzo H.L., Lee J.J., Koguchi Y., Blauvelt A. Circulating Th17, Th22, and Th1 cells are increased in psoriasis. J Invest Dermatol 2010, 130:1373-1383.
73. Novelli L., Chimenti M.S., Chiricozzi A., Perricone R. The new era for the treatment of psoriasis and psoriatic arthritis: perspectives and validated strategies. Autoimmun Rev 2014, 13:64-69.
74. Nograles K.E., Zaba L.C., Guttman-Yassky E., Fuentes-Duculan J., Suarez-Farinas M., Cardinale I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 2008, 159:1092-1102.
75. Ahlehoff O., Gislason G.H., Charlot M., Jorgensen C.H., Lindhardsen J., Olesen J.B., Abildstrom S.Z., Skov L., Torp-Pedersen C., Hansen P.R. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med 2011, 270:147-157.
76. Shao S., He F., Yang Y., Yuan G., Zhang M., Yu X. Th17 cells in type 1 diabetes. Cell Immunol 2012, 280:16-21.
77. Molet S., Hamid Q., Davoine F., Nutku E., Taha R., Page N., et al. IL-17 is increased in asthmatic airways and induces human bronchial fibroblasts to produce cytokines. J Allergy Clin Immunol 2001, 108:430-438.
78. Wang Q, Li H, Yao Y, Xia D, Zhou J. The overexpression of heparin-binding epidermal growth factor is responsible for Th17-induced airway remodeling in an experimental asthma model. J Immunol 185: 834-41.
79. Bullens D.M., Truyen E., Coteur L., Dilissen E., Hellings P.W., Dupont L.J., et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx?. Respir Res 2006, 7:135.
80. Agache I., Ciobanu C., Agache C., Anghel M. Increased serum IL-17 is an independent risk factor for severe asthma. Respir Med 2010, 104:1131-1137.
81. Zou W., Restifo N.P. T(H)17 cells in tumour immunity and immunotherapy. Nat Rev Immunol 2010, 10:248-256.
82. Gnerlich J.L., Mitchem J.B., Weir J.S., Sankpal N.V., Kashiwagi H., Belt B.A., et al. Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 2010, 185:4063-4071.
83. Muranski P., Borman Z.A., Kerkar S.P., Klebanoff C.A., Ji Y., Sanchez-Perez L., et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011, 35:972-985.
84. Miyahara Y., Odunsi K., Chen W., Peng G., Matsuzaki J., Wang R.F. Generation and regulation of human CD4+ IL-17-producing T cells in ovarian cancer. Proc Natl Acad Sci U S A 2008, 105:15505-15510.
85. Zhang J.P., Yan J., Xu J., Pang X.H., Chen M.S., Li L., et al. Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 2009, 50:980-989.
86. Kesselring R., Thiel A., Pries R., Trenkle T., Wollenberg B. Human Th17 cells can be induced through head and neck cancer and have a functional impact on HNSCC development. Br J Cancer 2010, 103:1245-1254.
87. Maruyama T., Kono K., Mizukami Y., Kawaguchi Y., Mimura K., Watanabe M., et al. Distribution of Th17 cells and FoxP3(+) regulatory T cells in tumor-infiltrating lymphocytes, tumor-draining lymph nodes and peripheral blood lymphocytes in patients with gastric cancer. Cancer Sci 2010, 101:1947-1954.
88. Tosolini M., Kirilovsky A., Mlecnik B., Fredriksen T., Mauger S., Bindea G., et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer. Cancer Res 2011, 71:1263-1271.
89. Su X., Ye J., Hsueh E.C., Zhang Y., Hoft D.F., Peng G. Tumor microenvironments direct the recruitment and expansion of human Th17 cells. J Immunol 2010, 184:1630-1641.
90. He S., Fei M., Wu Y., Zheng D., Wan D., Wang L., et al. Distribution and clinical significance of th17 cells in the tumor microenvironment and peripheral blood of pancreatic cancer patients. Int J Mol Sci 2011, 12:7424-7437.
91. Kuang D.M., Peng C., Zhao Q., Wu Y., Chen M.S., Zheng L. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells. Hepatology 2010, 51:154-164.
92. Chen X., Wan J., Liu J., Xie W., Diao X., Xu J., et al. Increased IL-17-producing cells correlate with poor survival and lymphangiogenesis in NSCLC patients. Lung Cancer 2010, 69:348-354.
93. Zhang Y.L., Li J., Mo H.Y., Qiu F., Zheng L.M., Qian C.N., et al. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer 2010, 9:4.
94. Kryczek I., Banerjee M., Cheng P., Vatan L., Szeliga W., Wei S., et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009, 114:1141-1149.
95. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
96. Wilke C.M., Kryczek I., Wei S., Zhao E., Wu K., Wang G., et al. Th17 cells in cancer: help or hindrance?. Carcinogenesis 2011, 32:643-649.
97. Kryczek I., Wei S., Szeliga W., Vatan L., Zou W. Endogenous IL-17 contributes to reduced tumor growth and metastasis. Blood 2009, 114:357-359.
98. Wang L., Yi T., Kortylewski M., Pardoll D.M., Zeng D., Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009, 206:1457-1464.
99. Lelu K., Laffont S., Delpy L., Paulet P.E., Perinat T., Tschanz S.A., et al. Estrogen receptor alpha signaling in T lymphocytes is required for estradiol-mediated inhibition of Th1 and Th17 cell differentiation and protection against experimental autoimmune encephalomyelitis. J Immunol 2011, 187:2386-2393.
100. Lee J.H., Ulrich B., Cho J., Park J., Kim C.H. Progesterone promotes differentiation of human cord blood fetal T cells into T regulatory cells but suppresses their differentiation into Th17 cells. J Immunol 2011, 187:1778-1787.
101. Duffy M.M., Ritter T., Ceredig R., Griffin M.D. Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2011, 2:34.
102. Yi T., Song S.U. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res 2012, 35:213-221.
103. Ghannam S., Pene J., Torcy-Moquet G., Jorgensen C., Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 2010, 185:302-312.
104. Lee J.J., Jeong H.J., Kim M.K., Wee W.R., Lee W.W., Kim S.U., et al. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function. Purinergic Signal 2014, 10(2):357-365.
105. Luz-Crawford P., Noel D., Fernandez X., Khoury M., Figueroa F., Carrion F., et al. Mesenchymal stem cells repress Th17 molecular program through the PD-1 pathway. PLoS One 2012, 7:e45272.
106. Qu X., Liu X., Cheng K., Yang R., Zhao R.C. Mesenchymal stem cells inhibit Th17 cell differentiation by IL-10 secretion. Exp Hematol 2012, 40:761-770.
107. Duffy M.M., Pindjakova J., Hanley S.A., McCarthy C., Weidhofer G.A., Sweeney E.M., et al. Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 2011, 41:2840-2851.
108. Carrion F., Nova E., Luz P., Apablaza F., Figueroa F. Opposing effect of mesenchymal stem cells on Th1 and Th17 cell polarization according to the state of CD4+ T cell activation. Immunol Lett 2011, 135:10-16.
109. Svobodova E., Krulova M., Zajicova A., Pokorna K., Prochazkova J., Trosan P., et al. The role of mouse mesenchymal stem cells in differentiation of naive T-cells into anti-inflammatory regulatory T-cell or proinflammatory helper T-cell 17 population. Stem Cells Dev 2012, 21:901-910.
110. Park M.J., Park H.S., Cho M.L., Oh H.J., Cho Y.G., Min S.Y., et al. Transforming growth factor beta-transduced mesenchymal stem cells ameliorate experimental autoimmune arthritis through reciprocal regulation of Treg/Th17 cells and osteoclastogenesis. Arthritis Rheum 2011, 63:1668-1680.
111. Gonzalez M.A., Gonzalez-Rey E., Rico L., Buscher D., Delgado M. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009, 60:1006-1019.
112. Zhou B., Yuan J., Zhou Y., Ghawji M., Deng Y.P., Lee A.J., et al. Administering human adipose-derived mesenchymal stem cells to prevent and treat experimental arthritis. Clin Immunol 2011, 141:328-337.
113. Wang Q., Li X., Luo J., Zhang L., Ma L., Lv Z., et al. The allogeneic umbilical cord mesenchymal stem cells regulate the function of T helper 17 cells from patients with rheumatoid arthritis in an in vitro co-culture system. BMC Musculoskelet Disord 2012, 13:249.
114. Bai L., Lennon D.P., Eaton V., Maier K., Caplan A.I., Miller S.D., et al. Human bone marrow-derived mesenchymal stem cells induce Th2-polarized immune response and promote endogenous repair in animal models of multiple sclerosis. Glia 2009, 57:1192-1203.
115. Guo Y., Chan K.H., Lai W.H., Siu C.W., Kwan S.C., Tse H.F., et al. Human mesenchymal stem cells upregulate CD1dCD5(+) regulatory B cells in experimental autoimmune encephalomyelitis. Neuroimmunomodulation 2013, 20:294-303.
116. Eljaafari A., Tartelin M.L., Aissaoui H., Chevrel G., Osta B., Lavocat F., et al. Bone marrow-derived and synovium-derived mesenchymal cells promote Th17 cell expansion and activation through caspase 1 activation: contribution to the chronicity of rheumatoid arthritis. Arthritis Rheum 2012, 64:2147-2157.
117. Darlington P.J., Boivin M.N., Renoux C., Francois M., Galipeau J., Freedman M.S., et al. Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: implication for multiple sclerosis. Ann Neurol 2010, 68:540-545.